Significant Revenue Growth Amidst Strategic Shifts and Clinical Developments
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2024 Earnings Call Transcript May 9, 2024 Amylyx Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.75071 EPS, expectations were $0.24. AMLX isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. My name […]
Amylyx Pharmaceuticals (AMLX) delivered earnings and revenue surprises of -291.67% and 21.74%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?